Assessment of Patients for Long-Acting Injectable Antipsychotic Use
|
|
|
|
|
|
|
|
|
|
|
| |
|
Poor Adherence to Oral Antipsychotic Medications?
|
| |
| |
|
|
|
NO
|
YES
|
|
|
|
|
|
|
Consider patient preference to determine staying on oral or switching to injectable medication.
|
|
Is Patient amenable to injectables?
| NO
|
Is patient afraid of needles or unwilling to take medication for their condition
| NO
|
Revisit injectables at a later date
|
|
|
|
|
YES
|
|
YES
|
|
|
|
| |
|
Diagnosis
|
|
Address fears and emphasize importance of adherence
|
| |
|
|
|
|
|
|
|
|
|
|
|
Schizophrenia or Schizoaffective Disorder
|
|
Bipolar 1 Disorder
|
|
Other
|
|
Long acting injectables not Indicated
|
|
|
|
|
|
|
|
|
|
|
|
Has patient been stable on Paliperidone (invega Sustenna) IM q month for at least 4 months?
(dose range 25-150mg IM q month)
|
|
Patient stabilized on oral risperidone?
| NO
|
Long- acting injectable risperidone not indicated. Leave on oral medication or consider Abilify Maintena 300mg-400mg IM q month
|
| |
|
|
YES
|
NO
|
|
YES
|
|
|
|
|
|
Consider switching to (Invega Trinza) IM injection every three months.
(dose range 175-525mg)
|
|
Consider either: Invega Sustenna 25-150mg IM q month
OR
Abililfy Maintena
300-400mg IM q month
OR
Risperdal Consta
12.5mg-50mg IM q 14 days
|
|
Consider Risperdal Consta 12.5mg-50mg IM q 2 weeks
|
| |
|
|
|
|
|
|
|
|
|
|
| |
| |
| |
| |
|
|
|
|
|
|
|
|
|